Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells
Posted by Corey Marcath on
Sheep Red Blood Cells from Innovative Research was used in the following study:
Tomasz Sewastianik , Maria Luisa Guerrera , Keith Adler , Peter S. Dennis , Kyle Wright , Vignesh Shanmugam , Ying Huang , Helen Tanton , Meng Jiang , Amanda Kofides , Maria G. Demos , Audrey Dalgarno , Neil A. Patel , Anwesha Nag , Geraldine S. Pinkus , Guang Yang , Zachary R. Hunter , Petr Jarolim , Nikhil C. Munshi , Steven P. Treon , Ruben D. Carrasco
LYMPHOID NEOPLASIA
November 12 2019
“…MYD88L265P is the most common mutation in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (LPL/WM) and one of the most frequent in poor-prognosis subtypes of diffuse large B-cell lymphoma (DLBCL). Although inhibition of the mutated MYD88 pathway has an adverse impact on LPL/WM and DLBCL cell survival, its role in lymphoma initiation remains to be clarified… To induce T-cell–dependent B-cell responses and GC formation, which facilitated cell sorting and flow cytometry analysis in young animals, mice were immunized by intraperitoneal injection of 5 × 108 sheep red blood cells (Innovative Research, Novi, MI) in 200 μL of phosphate-buffered saline and analyzed 10 days later, as described…”
Related products available from Innovative Research also include:
Sheep Red Blood Cells Packed 100%
Sheep Red Blood Cells Packed 10%